Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.

Kensei YamaguchiNozomu FuseYoshito KomatsuHirofumi FujiiShuichi HironakaYasushi OmuroKei MuroHirofumi YasuiShinya UedaTomohiro NishinaMorihiro WatanabeAtsushi Ohtsu

Published in: Japanese journal of clinical oncology (2021)

Overall, the addition of cetuximab to S-1 plus cisplatin was well tolerated in patients with advanced gastric cancer but provided no additional clinical benefit in this study. ClinicalTrials.gov identifier: NCT01388790.

Keyphrases

phase ii study
locally advanced
neoadjuvant chemotherapy
rectal cancer
open label
squamous cell carcinoma
metastatic colorectal cancer
radiation therapy
wild type
stem cells
clinical trial
randomized controlled trial
lymph node
mesenchymal stem cells
smoking cessation
replacement therapy